Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells
Longeveron has received a Chinese patent covering potency assay methods used to assess human mesenchymal stem cells from multiple tissue sources and induced pluripotent stem cells, extending the company’s patent rights in China through 2041.
Key findings
- Longeveron has received a Chinese patent covering potency assay methods for human mesenchymal stem cells.
- The patent applies to MSCs from multiple tissue sources, including bone marrow, adipose tissue, umbilical cord, and placenta, as well as cells differentiated from induced pluripotent stem cells.
- The company says the patent adds to its global portfolio of 52 patents and provides rights in China through 2041.
Longeveron has been granted a patent by the China National Intellectual Property Administration for methods of assessing the potency of human mesenchymal stem cells (MSCs). Potency assays are tests used to measure the biological activity of a cell therapy product, and they are an important part of cell therapy development and approval.
According to the company, the patent covers MSCs derived from bone marrow, adipose tissue, peripheral blood, lung, heart, amniotic fluid, inner organs, amniotic membrane, umbilical cord, and placenta, as well as MSCs differentiated from induced pluripotent stem cells (iPSCs). The patent, titled “Potency Assay,” gives Longeveron patent rights in China through 2041, assuming required annuity fees are paid.
“This patent issuance adds to our growing international portfolio of 52 patents protecting the novelty of our cell-based therapeutic products globally,” said Dr. Joshua M. Hare, Executive Chairman and Chief Science Officer of Longeveron. “We believe the breadth and strength of our global intellectual property portfolio is a strategic asset as Longeveron continues to advance its mission of advancing stem cell therapies for the benefit of patients and their families.”
Where this fits in Longeveron’s pipeline
Longeveron’s lead investigational product is laromestrocel (Lomecel-B), an allogeneic mesenchymal stem cell therapy made from bone marrow cells collected from young, healthy adult donors. The company has previously studied laromestrocel in Phase 1 and 2 trials for Alzheimer’s disease and aging-related frailty, and in a Phase 1 trial for hypoplastic left heart syndrome (HLHS).
Longeveron is currently running a Phase 2b trial of laromestrocel in HLHS. The company says results are expected in the third quarter of 2026 and may support a future Biologics License Application to the FDA for that indication, depending on the study outcome.
Regulatory snapshot
Longeveron says its laromestrocel programs have received five FDA designations:
- HLHS: Orphan Drug, Fast Track, and Rare Pediatric Disease designations
- Alzheimer’s disease: Regenerative Medicine Advanced Therapy and Fast Track designations
More information: www.longeveron.com
Want to keep up on regenerative medicine? Get the weekly newsletter here.
